With participation from Baillie Gifford, Loyal’s latest funding builds on recent regulatory milestones and brings the company closer to market readiness
Pioneering canine longevity company advances lead lifespan extension drug towards approval with acceptance of the Target Animal Safety section from the FDA’s Center for Veterinary Medicine
